<p>，/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者针对 aTyr Pharma, Inc.（&#34;aTyr&#34;或&#34;公司&#34;）（NASDAQ: ATYR）提起的集体诉讼，该诉讼因违反 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条而提起。</p>
<p>在 2025 年 1 月 16 日至 2025 年 9 月 12 日期间（包括该日期）（&#34;集体诉讼期间&#34;）购买了公司证券的投资者，鼓励在 2025 年 12 月 8 日之前联系该事务所。</p>
<p>如果您是遭受损失的股东，请点击此处参与。</p>
<p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
<p>本案的集体尚未获得认证，直到认证发生之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
<p>根据投诉，公司向市场发布了虚假和误导性声明。aTyr 及其高管对 Efzofitimod 的第三阶段试验的强制减药研究设计表示信心。公司隐瞒了该药物使患者完全减少类固醇使用的能力。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有实质性误导性的。当市场了解到 aTyr 的真相时，投资者遭受了损失。</p>
<p>加入本案以追回您的损失</p>
<p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
<p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
<p><strong>联系方式：</strong></p>
<p>Schall 律师事务所</p>
<p>Brian Schall, Esq.,</p>
<p>www.schallfirm.com</p>
<p>办公室：310-301-3335</p>
<p>[email protected]</p>
<p>来源：Schall 律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9TEE0MTEwNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgwMjE0UFJfTkVXU19VU1BSX19fX19MQTQxMTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9TEE0MTEwNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgwMjE0UFJfTkVXU19VU1BSX19fX19MQTQxMTA2"/></p>

<p>Schall 律师事务所宣布对 aTyr Pharma, Inc.提起集体诉讼，指控其证券欺诈，声称关于 Efzofitimod 的第三阶段试验存在虚假和误导性陈述。鼓励在 2025 年 1 月 16 日至 2025 年 9 月 12 日期间购买证券的投资者在 2025 年 12 月 8 日之前加入诉讼，以追回损失</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (&#34;aTyr&#34; or &#34;the Company&#34;) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者针对 aTyr Pharma, Inc.（&#34;aTyr&#34;或&#34;公司&#34;）（NASDAQ: ATYR）提起的集体诉讼，该诉讼因违反 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条而提起。</p>
</div><p>Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the &#34;Class Period&#34;), are encouraged to contact the firm before December 8, 2025.</p>
<div class="lb-trans"><p>在 2025 年 1 月 16 日至 2025 年 9 月 12 日期间（包括该日期）（&#34;集体诉讼期间&#34;）购买了公司证券的投资者，鼓励在 2025 年 12 月 8 日之前联系该事务所。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请点击此处参与。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
</div><p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
<div class="lb-trans"><p>本案的集体尚未获得认证，直到认证发生之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
</div><p>According to the Complaint, the Company made false and misleading statements to the market. aTyr and its executives expressed confidence about the forced taper study design for the Phase 3 trial of Efzofitimod. The Company concealed the drug's capability to let patients taper their steroid usage completely. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about aTyr, investors suffered damages.</p>
<div class="lb-trans"><p>根据投诉，公司向市场发布了虚假和误导性声明。aTyr 及其高管对 Efzofitimod 的第三阶段试验的强制减药研究设计表示信心。公司隐瞒了该药物使患者完全减少类固醇使用的能力。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有实质性误导性的。当市场了解到 aTyr 的真相时，投资者遭受了损失。</p>
</div><p>Join the case to recover your losses</p>
<div class="lb-trans"><p>加入本案以追回您的损失</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律师事务所</p>
</div><p>Brian Schall, Esq.,</p>
<div class="lb-trans"><p>Brian Schall, Esq.,</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>Office: 310-301-3335</p>
<div class="lb-trans"><p>办公室：310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>来源：Schall 律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9TEE0MTEwNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgwMjE0UFJfTkVXU19VU1BSX19fX19MQTQxMTA2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA41106&amp;Transmission_Id=202512080214PR_NEWS_USPR_____LA41106&amp;DateId=20251208"/></p>

ATYR 投资者有机会与 Schall 律师事务所共同主导针对 aTyr Pharma, Inc.的证券欺诈诉讼